Efdelikofusp alfa 是一种双特异性 Fc 融合蛋白，由人 CD80 (B7.1) 的 N 端胞外结构域与人免疫球蛋白G4 (IgG4) Fc 片段融合，并作为 C 端部分与白细胞介素-2 变体 (IL-2v) 连接。Efdelikofusp alfa 具有潜在的免疫刺激、免疫检查点抑制和抗肿瘤活性。
Efzilonkofusp alfa 是一种双特异性 Fc 融合蛋白，由人 CD80 (B7.1) 的 N 端胞外结构域与人免疫球蛋白G4 (IgG4) Fc 片段融合，并作为 C 端部分与白细胞介素-2 变体 (IL-2v) 连接。Efzilonkofusp alfa 具有潜在的免疫刺激、免疫检查点抑制和抗肿瘤活性。
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) 是一种小鼠源 IgG1 κ 型抗体抑制剂，靶向 SARS-CoV-2 S protein。Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) 与 SARS-CoV-2 (严重急性呼吸综合征冠状病毒 2) 的刺突 (S) 蛋白中的受体结合域 (RBD) B 表位发生反应。Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) 可阻断 SARS-CoV-2 S 蛋白与血管紧张素转换酶 2 (ACE2) 的结合。Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) 可用于 SARS-CoV-2 感染的研究。
Efdelikofusp alfa 是一种双特异性 Fc 融合蛋白，由人 CD80 (B7.1) 的 N 端胞外结构域与人免疫球蛋白G4 (IgG4) Fc 片段融合，并作为 C 端部分与白细胞介素-2 变体 (IL-2v) 连接。Efdelikofusp alfa 具有潜在的免疫刺激、免疫检查点抑制和抗肿瘤活性。
Efzilonkofusp alfa 是一种双特异性 Fc 融合蛋白，由人 CD80 (B7.1) 的 N 端胞外结构域与人免疫球蛋白G4 (IgG4) Fc 片段融合，并作为 C 端部分与白细胞介素-2 变体 (IL-2v) 连接。Efzilonkofusp alfa 具有潜在的免疫刺激、免疫检查点抑制和抗肿瘤活性。
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) 是一种小鼠源 IgG1 κ 型抗体抑制剂，靶向 SARS-CoV-2 S protein。Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) 与 SARS-CoV-2 (严重急性呼吸综合征冠状病毒 2) 的刺突 (S) 蛋白中的受体结合域 (RBD) B 表位发生反应。Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) 可阻断 SARS-CoV-2 S 蛋白与血管紧张素转换酶 2 (ACE2) 的结合。Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) 可用于 SARS-CoV-2 感染的研究。
ZBTB7B; Zinc finger and BTB domain-containing protein 7B; Krueppel-related zinc finger protein cKrox; hcKrox; T-helper-inducing POZ/Krueppel-like factor; Zinc finger and BTB domain-containing protein 15; Zinc finger protein 67 homolog; Zfp-67; Zinc finger protein 857B; Zinc finger protein Th-POK
ZBTB7B; Zinc finger and BTB domain-containing protein 7B; Krueppel-related zinc finger protein cKrox; hcKrox; T-helper-inducing POZ/Krueppel-like factor; Zinc finger and BTB domain-containing protein 15; Zinc finger protein 67 homolog; Zfp-67; Zinc finger protein 857B; Zinc finger protein Th-POK
Basic domain helix loop helix protein class B 1 antibody; Basic helix loop helix protein class B 1 antibody; BHLHB antibody; bHLHB1 antibody; bHLHe19 antibody; Class B basic helix loop helix protein 1 antibody; Class B basic helix-loop-helix protein 1 antibody; class E basic helix loop helix protein 19 antibody; Class E basic helix-loop-helix protein 19 antibody; Human protein kinase C binding protein RACK17 antibody; Basic domain helix loop helix protein class B 1 antibody; Basic helix loop helix protein class B 1 antibody
Fas like protein; Apoptosis inducing protein TRICK2A/2B; Apoptosis inducing receptor TRAIL R2; CD 262; CD262; CD262 antigen; Cytotoxic TRAIL receptor 2; Death domain containing receptor for TRAIL/Apo 2L; Death domain containing receptor for TRAIL/Apo2L; D
Basic domain helix loop helix protein class B 1; Basic helix loop helix protein class B 1; BHLHB; bHLHB1; bHLHe19; Class B basic helix loop helix protein 1; Class B basic helix-loop-helix protein 1; class E basic helix loop helix protein 19; Class E basic helix-loop-helix protein 19; Human protein kinase C binding protein RACK17; Olig2; OLIG2_HUMAN; Oligo2; Oligodendrocyte lineage transcription factor 2; Oligodendrocyte specific bHLH transcription factor 2; Oligodendrocyte transcription factor 2; OTTHUMP00000067569; OTTHUMP00000067570; PRKCBP2; Protein kinase C binding protein 2; Protein kinase C binding protein RACK17; Protein kinase C-binding protein 2; Protein kinase C-binding protein RACK17; RACK17.
Histone methyltransferase SMYD2; HSKM B; HSKM-B; HSKMB; KMT3C; Lysine N-methyltransferase 3C; MGC119305; N lysine methyltransferase SMYD2; N-lysine methyltransferase SMYD2; SET and MYND domain containing 2; SET and MYND domain containing protein 2; SET and MYND domain-containing protein 2; Smyd2; SMYD2_HUMAN; Zinc finger MYND domain containing 14; ZMYND14.
BOP; CD8 beta opposite; CD8b opposite; Histone lysine N methyltransferase SMYD1; KMT3D; SET and MYND domain-containing protein 1; SMYD1; SMYD1_HUMAN; Zinc finger MYND domain containing 18; ZMYND18; ZMYND22; zinc finger, MYND domain containing 18.
Basic domain helix loop helix protein class B 1; Basic helix loop helix protein class B 1; BHLHB; bHLHB1; bHLHe19; Class B basic helix loop helix protein 1; Class B basic helix-loop-helix protein 1; class E basic helix loop helix protein 19
Basic domain helix loop helix protein class B 1; Basic helix loop helix protein class B 1; BHLHB; bHLHB1; bHLHe19; Class B basic helix loop helix protein 1; Class B basic helix-loop-helix protein 1; class E basic helix loop helix protein 19
B cell Oct binding protein 1; B cell specific coactivator OBF 1; B cell specific coactivator OBF1; B-cell-specific coactivator OBF-1; BOB 1; BOB-1; OBF 1; OBF1; OBF1_HUMAN; OCA B; OCA-B; OCAB; OCT binding factor 1; OCT-binding factor 1; POU class 2 associating factor 1; POU domain class 2 associating factor 1; POU domain class 2-associating factor 1; Pou2af1
"Basic helix loop helix domain containing class B protein 7 antibody; Basic helix-loop-helix domain-containing protein, class B, 7 antibody; bHLHB7 antibody; bHLHe20 antibody; Class B basic helix loop helix protein 7 antibody; Class B basic helix-loop-helix protein 7 antibody; Class E basic helix loop helix protein 20 antibody; Class E basic helix-loop-helix protein 20 antibody; Olig3 antibody; OLIG3_HUMAN antibody; "Basic helix loop helix domain containing class B protein 7 antibody; Basic helix-loop-helix domain-containing protein, class B, 7 antibody; bHLHB7 antibody; bHLHe20 antibody; Class B basic helix loop helix protein 7 antibody; Class B basic helix-loop-helix protein 7 antibody; Class E basic helix loop helix protein 20 antibody; Class E basic helix-loop-helix protein 20 antibody; Olig3 antibody; OLIG3_HUMAN antibody; Oligo3 antibody; Oligodendrocyte lineage transcription factor 3 antibody; Oligodendrocyte specific bHLH transcription factor 3 antibody; Oligodendrocyte transcription factor 3 antibody; "
Fas like protein; Apoptosis inducing protein TRICK2A/2B; Apoptosis inducing receptor TRAIL R2; CD 262; CD262; CD262 antigen; Cytotoxic TRAIL receptor 2; Death domain containing receptor for TRAIL/Apo 2L; Death domain containing receptor for TRAIL/Apo2L; D
Cancer/testis antigen 98; CT98; DKFZp686F1078; hKOC; IF2B3_HUMAN; IGF II mRNA binding protein 3; IGF-II mRNA-binding protein 3; IGF2 mRNA binding protein 3; IGF2 mRNA-binding protein 3; IGF2BP3; IMP 3; IMP-3; Insulin like growth factor 2 mRNA binding protein 3; Insulin-like growth factor 2 mRNA-binding protein 3; KH domain containing protein overexpressed in cancer; KH domain-containing protein overexpressed in cancer; KOC 1; KOC1; VICKZ 3; VICKZ family member 3; VICKZ3.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
